Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$25.39 USD
-0.93 (-3.53%)
Updated Oct 13, 2025 04:00 PM ET
After-Market: $25.45 +0.06 (0.24%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Beam Therapeutics Inc. has a market cap of $2.66B, which represents its share price of $26.32 multiplied by its outstanding shares number of 101.16M. As a mid-cap company, BEAM's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
BEAM 25.39 -0.93(-3.53%)
Will BEAM be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for BEAM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BEAM
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report?
BEAM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy?
CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?
CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock
Other News for BEAM
Slingshot Bullish appears for BEAM after 5.56% move
Pocket Pivot appears for BEAM after 3.22% move
HC Wainwright & Co. Reiterates Buy Rating for BEAM at $80 Target | BEAM Stock News
H.C. Wainwright Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)
Beam Therapeutics initiated with a Buy at Jefferies